Biopharmaceuticals

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five […]

Global biopharmaceutical company Amryt has signed a distribution agreement with Medison Pharma Canada to distribute Myalepta (metreleptin) in Canada. Amryt is a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising novel treatments for rare diseases. Medison is a commercial partner of global biotech companies that provide integrated services for biotech companies looking to […]

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers are optimised aptamer reagents. Based […]

Contract Research Organisation (CRO) Veramed has joined a community of global companies using business as a force for good. Veramed, provider of specialist statistics and programming services to biopharmaceutical companies, announced that it has been awarded a B Corporation certification. The certification addresses all parts of a business’ operations, covering key impact areas of governance, […]

Resilience in pharma and biotech supply chains is essential for the roll out of the Covid-19 vaccine, says Karl Lauri, ERP/MRP software manufacturer and distributor MRPeasy.com.  While the pandemic has highlighted the strength of the UK’s pharmaceutical and biotechnology sector, it has also shed light on the vulnerabilities of intricate, geographically extended and time-critical supply chains which needs to be prioritised. An efficient ERP/MRP ‘backbone’ will […]

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma. RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital […]

Phesi, provider of AI-based clinical development analytics products and solutions, is showcasing its data-driven clinical development approach at SCOPE Virtual Summit for Clinical Operations Executives 2021, in a case study session with international pharmaceutical company, Alfasigma. Phesi and Alfasigma are currently working together to maximise the value of priority medical assets, explore the use of […]

RedHill Biopharma, a specialty biopharmaceutical company, has announced that the first patient was dosed in its US Phase II/III study of orally-administered RHB-107 (upamostat)[i], an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care. Dror Ben-Asher, RedHill’s CEO said: “RedHill is rapidly advancing two Phase III-stage, orally-administered, novel molecules for […]

Genedata and IDBS, have entered into a strategic partnership to create synergies between their platforms. The combined solution will directly integrate IDBS digital solutions with the Genedata Biopharma Platform so that all R&D as well as manufacturing data can be seamlessly exchanged, processed, and interpreted along the entire biopharma workflow. This collaboration addresses the challenge […]

The human body has the capacity to produce an array of specialised T cells, which provide unique responses to a diverse range of tumour cells and pathogens. In its latest white paper, biopharmaceutical expert, Sartorius, explains why the modulation of T cells is an exciting prospect for the development of novel therapies for immuno-oncology –autoimmune […]

Global mammalian transient protein market revenues are projected to surpass US$ 540 million in 2020, according to a new study by Future Market Insights. The report also states that, innovations in automation and recombinant proteins will support market developments, however, prohibitive costs and complexity to maintain media purity remain challenges. Key takeaways on mammalian transient […]

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase I […]